[Neoadjuvant chemotherapy effective for small cell lung cancer in a nephrectomized patient].
A 67-year-old man, who was nephrectomized due to renal cell cancer 4 years ago, was admitted to examine a mass shadow in the right middle lung field. He was diagnosed as small cell lung cancer with TBLB. Because of impaired renal function, he was treated with CBDCA (300 mg/m2, day 1), THP (30 mg/m2, day 1) and oral etoposide (25 mg/body, for 21 days) without any renal complications. After 3 courses of chemotherapy, the lung CT showed scar lesion despite the disappearance on the chest X-ray, and a right lower lobectomy was performed. Malignant cells remained in the scar lesion, but not in the lymph nodes. These findings suggested the effectiveness of neoadjuvant chemotherapy. This newly-designed chemotherapy procedure is necessary for patients with renal complications.
Toyoda
T
T
Second Dept. of Internal Medicine, Kohori Hospital.
Okamoto
M
M
Fujii
M
M
Yonezu
S
S
Kumamoto
T
T
Umemoto
M
M
Saitoh
Y
Y
Okamura
A
A
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000601:surgery; D018288:Carcinoma, Small Cell / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D016609:Neoplasms, Second Primary; D009392:Nephrectomy
D005047:Etoposide; D004317:Doxorubicin; D016190:Carboplatin; C027260:pirarubicin